Anthrax test
This article was originally published in The Gray Sheet
Executive Summary
A new nanotechnology-based testing platform for detecting and diagnosing the anthrax toxin developed at FDA is more sensitive than current anthrax-detection tests, such as the enzyme-linked immunosorbent assay (ELISA), recent data show. FDA's europium nanoparticle-based immunoassay (ENIA) detected the protective antigen (PA) anthrax protein in quantities 100 times lower than ELISA, and detected PA in 100% of samples of mouse plasma compared to 36.4% with ELISA, according to results of a proof-of-concept study in the March issue of Clinical and Vaccine Immunology. Author Indira Hewlett, Ph.D., chief of FDA's Laboratory of Molecular Virology, says the test could be further developed and refined by partners in academia or industry
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.